Literature DB >> 14527927

Glucocorticoid inhibition of granulocyte macrophage-colony-stimulating factor from T cells is independent of control by nuclear factor-kappaB and conserved lymphokine element 0.

Martin W Bergmann1, Karl J Staples, Susan J Smith, Peter J Barnes, Robert Newton.   

Abstract

Release of granulocyte macrophage-colony-stimulating factor (GM-CSF) from T cells is important in the differentiation, maturation, and survival of inflammatory cells. Here the induction of GM-CSF expression from T cells was dependent on transcription and translation and was prevented by dexamethasone. In primary human CD3(+) T cells, up to 3.3 kb of human GM-CSF promoter was strongly activated by PMA + PHA. Mutations in either the -85/-76 nuclear factor (NF)-kappaB site or the activator protein-1 region in the -54/-31 conserved lymphokine element 0 (CLE0) site substantially reduced promoter activity. Both GM-CSF promoter and NF-kappaB-dependent constructs were unresponsive to dexamethasone whereas the release of GM-CSF was potently repressed. Analysis of GM-CSF mRNA and protein expression at various time points and the effect of adding dexamethasone after the stimulus revealed the existence of potent mechanisms of inhibition acting at a translational level. The expression of tristetraproline and HuR, proteins that bind the AU-rich element in the GM-CSF 3'-untranslated region was unaffected by dexamethasone and overall AU-rich element binding activity was unaltered. Taken together our data support an important role for the NF-kappaB and CLE0 sites in the transcriptional control of GM-CSF expression in primary human T cells and suggest that post-transcriptional/translational mechanisms are key mediators of glucocorticoid-dependent repression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527927     DOI: 10.1165/rcmb.2003-0295OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  11 in total

1.  GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation.

Authors:  Colleen S Curran; Michael D Evans; Paul J Bertics
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

Review 2.  Glucocorticosteroids: current and future directions.

Authors:  Peter J Barnes
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 3.  Biochemical basis of asthma therapy.

Authors:  Peter J Barnes
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

Review 4.  How corticosteroids control inflammation: Quintiles Prize Lecture 2005.

Authors:  Peter J Barnes
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

5.  Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100B.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  Int Immunol       Date:  2011-10-24       Impact factor: 4.823

6.  Nicotine enhances murine airway contractile responses to kinin receptor agonists via activation of JNK- and PDE4-related intracellular pathways.

Authors:  Yuan Xu; Yaping Zhang; Lars-Olaf Cardell
Journal:  Respir Res       Date:  2010-01-29

7.  Nuclear factor-kappaB does not mediate the inhibitory effects of dexamethasone on granulocyte-macrophage colony-stimulating factor expression.

Authors:  Martin W Bergmann; Karl J Staples; Peter J Barnes; Robert Newton
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

8.  Dexamethasone restrains ongoing expression of interleukin-23p19 in peripheral blood-derived human macrophages.

Authors:  Linda Palma; Carla Sfara; Antonella Antonelli; Mauro Magnani
Journal:  BMC Pharmacol       Date:  2011-07-26

Review 9.  Eosinophils in glioblastoma biology.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  J Neuroinflammation       Date:  2012-01-17       Impact factor: 8.322

Review 10.  Inhaled Corticosteroids.

Authors:  Peter J Barnes
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.